









Markets
/
Stocks
/
nasdaq-naut
/

Nautilus Biotechnology Inc

NAUT

1.510USD

0.000

Close 11/06, 16:00（ET）Quotes delayed by 15 min

190.72MMarket Cap

LossP/E TTM



Nautilus Biotechnology Inc

1.510

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nautilus Biotechnology Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nautilus Biotechnology Inc's Score

Industry at a Glance

Industry Ranking

210 / 501

Overall Ranking

370 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

2.500

Target Price

+65.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nautilus Biotechnology Inc Highlights

StrengthsRisks

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -2.59, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 57.12M shares, decreasing 6.05% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 619.91K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.45.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Nautilus Biotechnology Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 8.34, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -2.59, which is -52.73% below the recent high of -1.22 and -281.13% above the recent low of -9.86.

Score

Industry at a Glance

Previous score

8.34

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 210/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Nautilus Biotechnology Inc is 2.50, with a high of 2.50 and a low of 2.50.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

2.500

Target Price

+65.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Nautilus Biotechnology Inc

NAUT

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 8.98, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.68 and the support level at 0.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.47

Change

1.51

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.028

Buy

RSI(14)

59.215

Neutral

STOCH(KDJ)(9,3,3)

50.754

Sell

ATR(14)

0.254

High Vlolatility

CCI(14)

67.056

Neutral

Williams %R

42.105

Buy

TRIX(12,20)

2.687

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.558

Sell

MA10

1.461

Buy

MA20

1.284

Buy

MA50

0.968

Buy

MA100

0.854

Buy

MA200

0.953

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 45.22%, representing a quarter-over-quarter decrease of 44.09%. The largest institutional shareholder is The Vanguard, holding a total of 2.49M shares, representing 1.97% of shares outstanding, with 11.09% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Mallick (Parag)

20.69M

+0.07%

Andreessen Horowitz

17.65M

Patel (Sujal M)

17.44M

+1.16%

Perceptive Advisors LLC

12.59M

Cercano Management LLC

7.17M

Madrona Venture Group, LLC

6.02M

The Vanguard Group, Inc.

Star Investors

2.49M

-10.37%

Comprehensive Financial Management LLC

2.21M

Nazem (Farzad)

1.89M

Amazon.com Inc

1.46M

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.